top of page

Offspring Biosciences in research collaboration with BioArctic

We are proud to have the opportunity to work in collaboration together with BioArctic in this study we have been performing IHC binding of Lecanemab in Down syndrome and Alzheimer's disease

This study shows for or the first time, Lecanemab (an antibody with higher avidity for toxic Aβ aggregates), binding to Aβ protofibrils and plaques in people with Down syndrome is demonstrated

Lecanemab currently in phase 3 clinical studies and has shown to reduce brain amyloid levels in the brain of Alzheimer's disease patients


Recent Posts

See All


Post: Blog2_Post
bottom of page